Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The role of the Notch signaling pathway in tumor development is complex, with Notch1 functioning either as an oncogene or as a tumor suppressor in a context-dependent manner. To further define the role of Notch1 in tumor development, we systematically surveyed for tumor suppressor activity of Notch1 in vivo. We combined the previously described Notch1 intramembrane proteolysis-Cre (Nip1::Cre) allele with a floxed Notch1 allele to create a mouse model for sporadic, low-frequency loss of Notch1 heterozygosity. Through this approach, we determined the cell types most affected by Notch1 loss. We report that the loss of Notch1 caused widespread vascular tumors and organism lethality secondary to massive hemorrhage. These findings reflected a cell-autonomous role for Notch1 in suppressing neoplasia in the vascular system and provide a model by which to explore the mechanism of neoplastic transformation of endothelial cells. Importantly, these results raise concerns regarding the safety of chronic application of drugs targeting the Notch pathway, specifically those targeting Notch1, because of mechanism-based toxicity in the endothelium. Our strategy also can be broadly applied to induce sporadic in vivo loss of heterozygosity of any conditional alleles in progenitors that experience Notch1 activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, a chronic blockade of Notch signaling leads to vascular tumors of the liver, skin, ovary, testes and colon in mice [140, 141].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 4,859 · cited 6×
“We have previously reported that when N1::Cre is combined with the RosaLacZ reporter, the excision of the floxed stop cassette by ligand-dependent release of Cre indelibly labels cells that have experienced Notch1 activation.”
BackgroundInfluentialThe Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
Kopan, R., & Ilagan, M. X. G. (2009) · Cell · doi:10.1016/j.cell.2009.03.045 · Cited by 3,643 · cited 1×
“Introduction The Notch pathway is an evolutionarily conserved signaling mechanism that plays essential roles both during development and in the maintenance of adult tissue homeostasis in metazoan (1).”
BackgroundSelf-citationCre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121 · cited 8×
“CD105+CD45– proliferating liver ECs from N1::Crelo/flRosaEYFP/LacZ and N1::Crelo/+RosaEYFP/LacZ mice were collected (Figure 6A), and the DNA was purified and subjected to PCR amplification in order to detect the 3 Notch1 alleles: a normal promoter in the N1::Crelo allele, a floxed promoter in N1fl allele, and a rearra…”
BackgroundInfluentialActivating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715 · cited 2×
“Jeannet R, et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL [published online ahead of print September 9, 2010].”
Backgroundvan Es, J. H., van Gijn, M. E., Riccio, O., van den Born, M., Vooijs, M., Begthel, H., Cozijnsen, M., Robine, S., Winton, D. J., Radtke, F., et al. (2005) · Nature · doi:10.1038/nature03659 · Cited by 1,543 · cited 1×
“Considering that Notch1 is continuously required in multiple tissues during development and in the adult (33), especially in the gut (7, 34) and mammary gland (35) stem cell populations, a NIP::Cre allele coupled with floxed alleles of tumor suppressors offers a better model to mimic LOH disease development in human p…”
BackgroundNotch signaling is essential for vascular morphogenesis in mice
Krebs, L. T., Xue, Y., Norton, C. R., Shutter, J. R., Maguire, M., Sundberg, J. P., Gallahan, D., Closson, V., Kitajewski, J., Callahan, R., et al. (2000) · Genes & Development · doi:10.1101/gad.14.11.1343 · Cited by 1,060 · cited 1×
“Concomitant loss of signals from other Notch receptors, such as Notch4 in ECs (38) and Notch2/3 in pericytes (39–41), may have accelerated the tumor formation in their model (37).”
BackgroundBlockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032 · cited 4×
“The Notch pathway has emerged as a target to block angiogenesis in solid tumors (9, 10, 36) and eliminate tumor-initiating cells (13), either by the administration of anti-Dll4 antibody Figure 5 Characterization of vascular tumor cells.”
BackgroundResultInfluentialInhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986 · cited 4×
“The Notch pathway has emerged as a target to block angiogenesis in solid tumors (9, 10, 36) and eliminate tumor-initiating cells (13), either by the administration of anti-Dll4 antibody Figure 5 Characterization of vascular tumor cells.”
BackgroundResultInfluentialNotch1 functions as a tumor suppressor in mouse skin
Nicolas, M., Wolfer, A., Raj, K., Kummer, J. A., Mill, P., van Noort, M., Hui, C.-C., Clevers, H., Dotto, G. P., & Radtke, F. (2003) · Nature Genetics · doi:10.1038/ng1099 · Cited by 971 · cited 1×
“In contrast to gain-offunction mutations in Notch1 and their oncogenic role in T-ALL (3, 4), and perhaps in solid tumors, Notch1 loss-of-function mutations have only been implicated in a limited number of tumors, such as skin (2), where Notch1 loss promotes tumor formation non–cell-autonomously by creating a wound-lik…”
BackgroundNotch1 is required for the coordinate segmentation of somites
Conlon, R. A., Reaume, A. G., & Rossant, J. (1995) · Development · doi:10.1242/dev.121.5.1533 · Cited by 852
Cited by
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
“Conversely, blockade of DLL4 or Notch1 in the adult causes vascular tumors and hemorrhage (Liu et al., 2011; Yan et al., 2010).”
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Notch Signaling in Development, Tissue Homeostasis, and Disease
Siebel, C., & Lendahl, U. (2017) · Physiological Reviews · doi:10.1152/physrev.00005.2017 · Cited by 978
Endothelial Cell Heterogeneity
Aird, W. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006429 · Cited by 731
“A recent report showed a cell autonomous role for Notch1 in suppressing tumors of the endothelium (Liu et al. 2011).”
BackgroundVascular heterogeneity and specialization in development and disease
Potente, M., & Mäkinen, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.36 · Cited by 653
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review
KONTOMANOLIS, E. N., KOUTRAS, A., SYLLAIOS, A., SCHIZAS, D., MASTORAKI, A., GARMPIS, N., DIAKOSAVVAS, M., ANGELOU, K., TSATSARIS, G., PAGKALOS, A., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14622 · Cited by 389
A critical role for TCF-1 in T-lineage specification and differentiation
Weber, B. N., Chi, A. W.-S., Chavez, A., Yashiro-Ohtani, Y., Yang, Q., Shestova, O., & Bhandoola, A. (2011) · Nature · doi:10.1038/nature10279 · Cited by 429
Tumor Vessel Normalization by Chloroquine Independent of Autophagy
Maes, H., Kuchnio, A., Peric, A., Moens, S., Nys, K., De Bock, K., Quaegebeur, A., Schoors, S., Georgiadou, M., Wouters, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.025 · Cited by 410
“, 2011), and its inhibition evokes vascular remodeling and hyperbranching (Dill et al., 2012; Liu et al., 2011; Yan et al., 2010), properties that could explain CQ’s vessel normalization effects if its activity relied on Notch1 activation.”
BackgroundFrom Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling
Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.018 · Cited by 374
Notch Signaling and the Skeleton
Zanotti, S., & Canalis, E. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1002 · Cited by 321
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“Moreover, a chronic blockade of Notch signaling leads to vascular tumors of the liver, skin, ovary, testes and colon in mice [140, 141].”
BackgroundTargeting Notch in oncology: the path forward
Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00091-3 · Cited by 270
The Regulation of Valvular and Vascular Sclerosis by Osteogenic Morphogens
Boström, K. I., Rajamannan, N. M., & Towler, D. A. (2011) · Circulation Research · doi:10.1161/circresaha.110.234278 · Cited by 257
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Sancho, R., Cremona, C. A., & Behrens, A. (2015) · EMBO reports · doi:10.15252/embr.201540188 · Cited by 195
“However, because of the pleiotropic functions of Notch, loss or inhibition of Notch signalling can be pro-tumorigenic in other tissues such as skin and vasculature and result in serious side effects [98,99], precluding the systemic use of gamma-secretase inhibitors for colorectal cancer treatment.”
Notch signal strength controls cell fate in the haemogenic endothelium
Gama-Norton, L., Ferrando, E., Ruiz-Herguido, C., Liu, Z., Guiu, J., Islam, A. B. M. M. K., Lee, S.-U., Yan, M., Guidos, C. J., López-Bigas, N., et al. (2015) · Nature Communications · doi:10.1038/ncomms9510 · Cited by 171
Self-citationEGFL7: a unique angiogenic signaling factor in vascular development and disease
Nichol, D., & Stuhlmann, H. (2012) · Blood · doi:10.1182/blood-2011-10-322446 · Cited by 162
Blockade of individual Notch ligands and receptors controls graft-versus-host disease
Tran, I. T., Sandy, A. R., Carulli, A. J., Ebens, C., Chung, J., Shan, G. T., Radojcic, V., Friedman, A., Gridley, T., Shelton, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65477 · Cited by 165
A systems biology view of blood vessel growth and remodelling
Logsdon, E. A., Finley, S. D., Popel, A. S., & Gabhann, F. M. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12164 · Cited by 187
The double-edged sword of Notch signaling in cancer
South, A. P., Cho, R. J., & Aster, J. C. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.01.017 · Cited by 157
Jabs, M., Rose, A. J., Lehmann, L. H., Taylor, J., Moll, I., Sijmonsma, T. P., Herberich, S. E., Sauer, S. W., Poschet, G., Federico, G., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029733 · Cited by 152
Chiorean, E. G., LoRusso, P. M., Strother, R. M., Diamond, J. R., Younger, A., Messersmith, W. A., Adriaens, L., Liu, L., Kao, R., DiCioccio, A. T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2797 · Cited by 153
Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer
Roti, G., Carlton, A. L., Ross, K. N., Markstein, M., Pajcini, K. V., Su, A. H., Perrimon, N., Pear, W. S., Kung, A. L., Blacklow, S. C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.015 · Cited by 149
“Additional murine studies indicate that Notch signaling may have a tumor suppressive function in other cell lineages as well, including myeloid progenitors (Klinakis et al., 2011) and endothelial cells (Liu et al., 2011; Yan et al., 2010).”
Cancer stem cells in lung cancer: Evidence and controversies
Alamgeer, M., Peacock, C. D., Matsui, W. H., Ganju, V., & Watkins, D. N. (2013) · Respirology · doi:10.1111/resp.12094 · Cited by 158
Notch signaling in developmental and tumor angiogenesis
Kofler, N. M., Shawber, C. J., Kangsamaksin, T., Reed, H. O., Galatioto, J., & Kitajewski, J. (2011) · Genes & Cancer · doi:10.1177/1947601911423030 · Cited by 142
The Notch Pathway in Breast Cancer Progression
Kontomanolis, E. N., Kalagasidou, S., Pouliliou, S., Anthoulaki, X., Georgiou, N., Papamanolis, V., & Fasoulakis, Z. N. (2018) · The Scientific World JOURNAL · doi:10.1155/2018/2415489 · Cited by 142
Dill, M. T., Rothweiler, S., Djonov, V., Hlushchuk, R., Tornillo, L., Terracciano, L., Meili‐Butz, S., Radtke, F., Heim, M. H., & Semela, D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.052 · Cited by 139
Oncogenes and tumor suppressor genes: functions and roles in cancers
Dakal, T. C., Dhabhai, B., Pant, A., Moar, K., Chaudhary, K., Yadav, V., Ranga, V., Sharma, N. K., Kumar, A., Maurya, P. K., et al. (2024) · MedComm · doi:10.1002/mco2.582 · Cited by 172
Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor
Zheng, W., Tammela, T., Yamamoto, M., Anisimov, A., Holopainen, T., Kaijalainen, S., Karpanen, T., Lehti, K., Ylä-Herttuala, S., & Alitalo, K. (2011) · Blood · doi:10.1182/blood-2010-11-317800 · Cited by 132
“20 haploinsufficiency resulted in vascular tumors.(37) In addition, the differences between the endothelial Notch receptors in zebrafish (Notch1b and Notch6), and mammals”
Dll4-Notch signaling as a therapeutic target in tumor angiogenesis
Kuhnert, F., Kirshner, J. R., & Thurston, G. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-20 · Cited by 135
Liu, Z., Chen, S., Boyle, S., Zhu, Y., Zhang, A. J., Piwnica-Worms, D. R., Ilagan, M. X. G., & Kopan, R. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.05.022 · Cited by 112
“The importance of the ECD in the kidney epithelial cell is also reflected in the labeling frequencies of N1::Cre and N2::Cre reporter mice (Liu et al., 2011; Morimoto et al., 2010; Vooijs et al., 2007), in which the release of Cre recombinase is solely determined by theNotch ECD.”
InfluentialSelf-citationSada, A., Hasegawa, K., Pui, H., & Saga, Y. (2011) · Stem Cells · doi:10.1002/stem.790 · Cited by 110
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry
Kluk, M., Ashworth, T. D., Wang, H., Knoechel, B., Mason, E. F., Morgan, E. A., Dorfman, D. M., Pinkus, G., Weigert, O., Hornick, J. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067306 · Cited by 111
“Similarly, loss of notch1 function in vascular endothelium leads to angiosarcoma-like proliferations in mice [19,20].”
Notch: Architect, Landscaper, and Guardian of the Intestine
Vooijs, M., Liu, Z., & Kopan, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.003 · Cited by 100
Self-citationHajdu-Cheney syndrome: a review
CANALIS, E. M., & Zanotti, S. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0200-y · Cited by 97
“However, reduced Notch signaling can result in the formation of vascular tumors in experimental animals [41].”
BackgroundNotch Signaling in Neuroendocrine Tumors
Crabtree, J. S., Singleton, C. S., & Miele, L. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00094 · Cited by 95
“For example, Notch1 is an oncogene in most systems, but in skin (127), some squamous epithelia (128), vasculature (129, 130), and potentially NETs, it behaves as a tumor suppressor (15).”
BackgroundLiu, Z., Brunskill, E., Varnum-Finney, B., Zhang, C., Zhang, A., Jay, P. Y., Bernstein, I., Morimoto, M., & Kopan, R. (2015) · Development · doi:10.1242/dev.125492 · Cited by 85
Self-citationAdam, M. G., Berger, C., Feldner, A., Yang, W.-J., Wüstehube-Lausch, J., Herberich, S. E., Pinder, M., Gesierich, S., Hammes, H.-P., Augustin, H. G., et al. (2013) · Circulation Research · doi:10.1161/circresaha.113.301686 · Cited by 84
“Such continuous Notch signaling is necessary to prevent the conversion into the tip cell phenotype,(9) to allow further vessel remodeling,(18) and even to prevent angiogenesis in mature vessels.(12,13)”
BackgroundNotch: a key regulator of tumor angiogenesis and metastasis.
Garcia, A. J., & Kandel, J. J. (2012) · PubMed · doi:10.14670/hh-27.151 · Cited by 89
“Mice engineered to develop spontaneous loss of Notch1 form vascular tumors in the liver with decreased survival (Liu et al., 2011).”
BackgroundSchulz, G. B., Wieland, E., Wüstehube‐Lausch, J., Boulday, G., Moll, I., Tournier‐Lasserve, E., & Fischer, A. (2015) · Stroke · doi:10.1161/strokeaha.114.007512 · Cited by 82
Boyle, S. C., Liu, Z., & Kopan, R. (2013) · Development · doi:10.1242/dev.100271 · Cited by 74
“…hypothesis that D ev el op m en t Notch signaling is involved in development of cells arising from the SM, we used activation-specific fate mapping (Liu et al., 2011; Vooijs et al., 2007) and identified patterns of Notch1 and Notch2 activity in SM-derived structures, including labeling of the…”
Self-citationTargeting Notch to overcome radiation resistance
Yahyanejad, S., Theys, J., & Vooijs, M. (2015) · Oncotarget · doi:10.18632/oncotarget.6714 · Cited by 79
“Cyclical (intermittent) dosing, dose adjustments and patient stratification are therefore important to minimize the toxicities of chemo- and radiation therapy [139, 142-146].”
BackgroundRegulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis
Mazzone, M., & Bergers, G. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114721 · Cited by 74
“Although some tumors grew slowly due to inefficient blood supply as the result of this non-productive angiogenesis, the approach was soon abandoned because Delta-like 4 blockade could lead to the formation of vascular neoplasms (15), and Notch-1 haplodeficiency was associated with the formation of vascular tumors and…”
BackgroundKocher, B. A., & Piwnica-Worms, D. R. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0503 · Cited by 69
Self-citationMechanisms in Endocrinology: Notch signaling in skeletal health and disease
Zanotti, S., & CANALIS, E. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0115 · Cited by 66
Targeting the Notch Pathway: Twists and Turns on the Road to Rational Therapeutics
Aster, J. C., & Blacklow, S. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0992 · Cited by 68
Cancer Stem Cells in Prostate Cancer Chemoresistance
Ni, J., Cozzi, P. J., Hao, J., Duan, W., Graham, P., Kearsley, J. H., & Li, Y. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140328152459 · Cited by 62
“A recent study raised concerns over targeting Notch pathway, in which silencing of Notch1 caused widespread vascular tumors and organism lethality secondary to massive haemorrhage especially in liver [155].”
BackgroundNotch Suppresses Angiogenesis and Progression of Hepatic Metastases
Banerjee, D., Hernandez, S. L., Garcia, A. J., Kangsamaksin, T., Sbiroli, E., Andrews, J. P., Forrester, L. A., Wei, N., Kadenhe‐Chiweshe, A. V., Shawber, C. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1493 · Cited by 63
“The activation of SEC due to Notch1 inhibition has previously been reported in mice with Notch1 loss of heterozygosity (30).”
BackgroundEndothelial notch signaling is essential to prevent hepatic vascular malformations in mice
Cuervo, H., Nielsen, C. M., Simonetto, D. A., Ferrell, L., Shah, V. H., & Wang, R. A. (2016) · Hepatology · doi:10.1002/hep.28713 · Cited by 59
“Mice with deletion of Notch1 develop hepatic vascular tumors,((6,7)) whereas deletion of Rbpj in mice results in venooclusive disease.”
BackgroundWong, K., Ludwig, L., Krijgsman, O., Adams, D. J., Wood, G. A., & van der Weyden, L. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049044 · Cited by 67
“Additionally, inhibition of NOTCH signaling induces the development of malignant vascular tumors in mice (Liu et al., 2011; Dill et al., 2012).”
Control of microRNA biogenesis and transcription by cell signaling pathways
Saj, A., & Lai, E. C. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.04.010 · Cited by 71
“com cient phenotypes have also been observed for mammalian Notch pathway components [25,26].”
BackgroundLung Cancer Stem Cells and Implications for Future Therapeutics
Wang, J., Li, Z., White, J. R., & Zhang, L. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-9844-4 · Cited by 57
New Approaches to Target T-ALL
Roti, G., & Stegmaier, K. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00170 · Cited by 57
Control of Blood Vessel Formation by Notch Signaling
Tetzlaff, F., & Fischer, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-89512-3_16 · Cited by 56
Chen, C., Durand, E. M., Wang, J., Zon, L. I., & Poss, K. D. (2013) · Development · doi:10.1242/dev.102053 · Cited by 50
“Luciferase-based imaging has been widely used in mice for monitoring gene expression, cell proliferation and migration, and bacterial and viral infections (Contag and Bachmann, 2002; Luker and Luker, 2008; Liu et al., 2011; Tinkum et al., 2011; Martínez-Corral et al., 2012; Maguire et al., 2013).”
MethodNotch functions in developmental and tumour angiogenesis by diverse mechanisms1
Kangsamaksin, T., Tattersall, I., & Kitajewski, J. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140233 · Cited by 48
Taming the Notch Transcriptional Regulator for Cancer Therapy
Tamagnone, L., Zacchigna, S., & Rehman, M. (2018) · Molecules · doi:10.3390/molecules23020431 · Cited by 49
“In transgenic mice undergoing progressive loss of Notch1 with age, a shorter life-span of about 10 months was observed due to widespread vascular tumors [96], such as liver hemangiomas, due to excessive proliferation of endothelial cells.”
BackgroundDll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer
Kuhnert, F., Chen, G., Coetzee, S., Thambi, N., Hickey, C., Shan, J., Kovalenko, P., Noguera‐Troise, I., Smith, E., Fairhurst, J. L., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3773 · Cited by 47
“Similarly, loss of Dll4 or Notch1 function in genetic mouse models led to the activation of liver endothelial cells and the formation of hepatic vascular lesions (34, 45).”
BackgroundNotch Signaling in Ocular Vasculature Development and Diseases
Dou, G., Wang, L., Wang, Y., & Han, H. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00256 · Cited by 46
The cautionary tale of side effects of chronic Notch1 inhibition
Ryeom, S. W. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45976 · Cited by 46
Notch1 Regulates the Effects of Matrix Metalloproteinase-9 on Colitis-Associated Cancer in Mice
Garg, P., Jeppsson, S., Dalmasso, G., Ghaleb, A. M., McConnell, B. B., Yang, V. W., Gewirtz, A. T., Merlin, D., & Sitaraman, S. V. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.056 · Cited by 47
Prostate cancer stem cells: Are they androgen-responsive?
Oldridge, E. E., Pellacani, D., Collins, A. T., & Maitland, N. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.008 · Cited by 61
Hasegawa, K., Okamura, Y., & Saga, Y. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06063-11 · Cited by 45
“We next examined N1IP::Cre knock-in mice, in which Credependent recombination is induced in cells that experienced activation of Notch1 signaling (19).”
BackgroundEndothelial cell malignancies: new insights from the laboratory and clinic
Wagner, M. J., Ravi, V., Menter, D. G., & Sood, A. K. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0013-2 · Cited by 41
“Studies in a separate mouse model confirmed that loss of Notch1 heterozygosity leads to endothelial cell neoplasms of varying histological grade with approximately the same penetrance; interestingly, the liver was the primary site.(53) However, few, if any, significant Notch abnormalities have been identified in the s…”
BackgroundUncontrolled angiogenic precursor expansion causes coronary artery anomalies in mice lacking Pofut1
Wang, Y., Wu, B., Lu, P., Zhang, D., Wu, B., Varshney, S., del Monte‐Nieto, G., Zhuang, Z., Charafeddine, R. A., Kramer, A. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00654-w · Cited by 43
Therapeutic promise and challenges of targeting DLL4/NOTCH1
Yan, M. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-17 · Cited by 40
“A recent study employing an elegant genetic model showed that loss of Notch1 caused widespread vascular tumors, particularly in the liver, further underscoring the potential safety concerns associated with continuous blockade of NOTCH1 signaling [30].”
Fraser, H. M., Hastings, J. M., Allan, D. J., Morris, K. D., Rudge, J. S., & Wiegand, S. J. (2012) · Endocrinology · doi:10.1210/en.2011-1688 · Cited by 44
“In contrast, stringent, chronic inhibition of Dll4/Notch signaling with high-affinity antibodies (52) or gene deletions can lead to vascular abnormalities in some tissues (53, 54).”
Loss of Notch1 Disrupts the Barrier Repair in the Corneal Epithelium
Movahedan, A., Afsharkhamseh, N., Sagha, H. M., Shah, J., Milani, B. Y., Milani, F. Y., Logothetis, H. D., Chan, C., & Djalilian, A. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069113 · Cited by 35
Tu, J., Li, Y., & Hu, Z. (2014) · BioMed Research International · doi:10.1155/2014/368082 · Cited by 37
“The majority of knowledge implicating the Notch signaling in vessel homeostasis and development has arisen through gain and loss of function studies in mice [17, 18].”
BackgroundHasebe, T., Fujimoto, K., Kajita, M., Fu, L., Shi, Y., & Ishizuya‐Oka, A. (2016) · Stem Cells · doi:10.1002/stem.2544 · Cited by 37
Walter, L., Pujada, A., Bhatnagar, N., Bialkowska, A. B., Yang, V. W., Laroui, H., & Garg, P. (2016) · Oncotarget · doi:10.18632/oncotarget.13406 · Cited by 34
Anti-angiogenic alternatives to VEGF blockade
Khan, K. A., & Bicknell, R. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9769-3 · Cited by 33
“Similarly low frequency genetic loss of Notch1 in adult mice leads to increased endothelial proliferation and the formation of vascular tumours [60].”
BackgroundWang, J., Liu, Q., Gao, H., Wan, D., Li, C., Li, Z., & Zhang, Y. (2017) · Tumor Biology · doi:10.1177/1010428317706203 · Cited by 31
Sewell, F. R., Chapman, K. L., Couch, J. A., Dempster, M., Heidel, S. M., Loberg, L. I., Maier, C. C., MacLachlan, T. K., Todd, M. D., & van der Laan, J. W. (2017) · mAbs · doi:10.1080/19420862.2017.1324376 · Cited by 30
“Heterozygous DLL4 knockout mice show embryonic lethality due to vascular abnormalities, and more recent experiments show that conditional knockout of Notch 1 can also lead to the development of vascular tumors in mice.(34,35) Targeting DLL4 with an antibody (anti-DLL4 IgG1) yielded robust anti-tumor activity in severa…”
BackgroundLiu, Z., Brown, A. J., Fisher, D., Wu, Y., Warren, J., & Cui, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149379 · Cited by 33
“Immunohistostaining was performed as described in [39] with modifications.”
MethodSelf-citationTherapeutic targets associated to E-cadherin dysfunction in gastric cancer
Carneiro, P., Figueiredo, J., Bordeira–Carriço, R., Fernandes, M. S., Carvalho, J., Oliveíra, C., & Seruca, R. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.827174 · Cited by 33
“reported that chronic inhibition of Notch-1 resulted in widespread vascular tumors, raising concerns regarding the currently used Notch-targeting therapies in humans, such as Notch-1 antibodies, decoy ligands, or g-secretase inhibitors [173].”
BackgroundAngiogenic growth factor expression in benign and malignant vascular tumours
Young, R., Fernando, M. S., Hughes, D. J., Brown, N. J., & Woll, P. J. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.06.010 · Cited by 26
Wang, B., Yang, B., Yang, H., Wang, J., Hu, S., Gao, Y., & Bu, X. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.005 · Cited by 24
Combining Notch inhibition with current therapies for breast cancer treatment
Brennan, K. R., & Clarke, R. B. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012457437 · Cited by 27
“It is also worth noting that long-term treatment with Notch pathway inhibitors is associated with development of vascular tumours [Liu et al. 2011; Yan et al. 2010].”
BackgroundVascular-targeted agents for the treatment of angiosarcoma
Young, R., Woll, P. J., Staton, C. A., Reed, M., & Brown, N. J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2345-0 · Cited by 25
“Interestingly, pan inhibition of Notch signalling resulted in liver sinusoidal endothelial cell proliferation, intussusceptive angiogenesis, and the formation of hepatic vascular abnormalities, including angiosarcomas, in vivo[152, 153].”
BackgroundClinicopathological analysis of ATRX , DAXX and NOTCH receptor expression in angiosarcomas
Panse, G., Chrisinger, J. S. A., Leung, C. H., Ingram, D. R., Khan, S., Wani, K., Lin, H. Y., Lazar, A. J., & Wang, W. (2017) · Histopathology · doi:10.1111/his.13337 · Cited by 23
“Mouse models also show that inhibition of NOTCH signalling can induce hepatic vascular tumours, indicating a tumour suppressive role of the NOTCH pathway in these angiosarcomas.(16,17) NOTCH1 loss-offunction mutations and NOTCH2 aberrations have been reported in a subset of angiosarcomas.”
BackgroundMINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth
Ho, R. X.-Y., Meyer, R., Chandler, K. B., Ersoy, E., Park, M., Bondzie, P. A., Rahimi, N., Xu, H., Costello, C. E., & Rahimi, N. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy002 · Cited by 22
Targeting γ-secretase in breast cancer
Han, J., & Shen (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s26437 · Cited by 27
“75,76 Of note, vision deterioration occurred in two out of 36 patients receiving semagacestat while none was reported in patients receiving placebo in the phase II clinical trial mentioned above, 70 although whether vision deterioration was due to abnormal angiogenesis in retina was not reported.”
Liu, Z., Brunskill, E. W., Boyle, S., Chen, S., Turkoz, M., Guo, Y., Grant, R. L., & Kopan, R. (2015) · Development · doi:10.1242/dev.119529 · Cited by 20
Self-citationKalaitzidis, D., & Armstrong, S. A. (2011) · Nature · doi:10.1038/473159a · Cited by 16
Inhibition of Notch signaling attenuates pituitary adenoma growth in Nude mice
Zubeldía-Brenner, L., Winne, C. D., Perrone, S., Rodríguez‐Seguí, S. A., Willems, C., Ornstein, A. M., Lacau-Mengido, I. M., Vankelecom, H. E. J., Cristina, C., & Becú‐Villalobos, D. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0337 · Cited by 15
Marques, F. G., Carvalho, L., Sousa, J. S., Rino, J., Diegues, I., Poli, E., Pina, F., Saúde, L., & Santos, S. C. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-60129-9 · Cited by 15
Growth factor signaling pathways in vascular development and disease
Grant, Z. L., & Coultas, L. (2019) · Growth Factors · doi:10.1080/08977194.2019.1635591 · Cited by 15
“Inhibition of DLL4/Notch signaling in adults also causes hyper-proliferative vascular lesions in the liver and skin (Liu et al. 2011; Yan et al. 2010).”
BackgroundGeneration of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model
Rothweiler, S., Dill, M. T., Terracciano, L., Makowska, Z., Quagliata, L., Hlushchuk, R., Djonov, V., Heim, M. H., & Semela, D. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.141 · Cited by 13
Cheng, F., Pekkonen, P., & Ojala, P. M. (2012) · Future Microbiology · doi:10.2217/fmb.12.95 · Cited by 13
“In addition, a relatively recent report raised even more serious concerns for Notch receptor targeting by demonstrating that inactivation of Notch1 in mice may cause abnormal proliferation of endothelial tissue, leading to the development of vascular tumors, particularly in the liver [133].”
BackgroundInvestigational Notch and Hedgehog inhibitors – therapies for cardiovascular disease
Redmond, E. M., Guha, S., Walls, D., & Cahill, P. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.628658 · Cited by 16
“minimized the adverse effects of pan-Notch inhibition by selectively targeting Notch1, a recent new study suggests that Notch1 inhibition may also cause tumors [78] thereby necessitating further work on these inhibitors.”
BackgroundLiu, Z., Liu, Z., Walters, B. J., Owen, T., Kopan, R., & Zuo, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064903 · Cited by 12
“To overcome such limitations and to visualize Notch1 signaling more directly, we utilized a genetic lineage tracing approach involving Notch1 (Low)/+ and Notch1 (High)/+ mouse strains [26,29].”
BackgroundMethodInfluentialSelf-citationThe developmental origins of Notch-driven intrahepatic bile duct disorders
Lyons, A. M., & Boulter, L. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048413 · Cited by 14
“NOTCH1 is well documented to be cleaved at S1 by Furin or Furin-like convertases (Logeat et al., 1998; Gordon et al., 2009).”
BackgroundNOTCH1 regulates migration and invasion of skin cancer cells by E-cadherin repression
Wang, Z., Liu, L., Wang, M., Shen, M., Li, J., Liu, J., Li, C., Xin, C., Zhu, S., Mei, Q., et al. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1125-6 · Cited by 11
“Mammals have four NOTCH receptors (NOTCH1-4) [1].”
Fan, L., Liu, H., Zhu, G., Singh, S., Yu, Z., Wang, S., Luo, H., Liu, S., Xu, Y., Ge, J., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15904 · Cited by 11
Tu, J., Li, Y., Hu, Z., & Chen, Z. (2014) · Journal of neurosurgery · doi:10.3171/2013.12.jns131595 · Cited by 12
Bademci, G., Lachgar-Ruiz, M., Deokar, M., Zafeer, M. F., Abad, C., Baylan, M. Y., Ingham, N. J., Chen, J., Sineni, C. J., Vadgama, N., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204084119 · Cited by 11
Overview of Genetic Tools and Techniques to Study Notch Signaling in Mice
Gridley, T., & Groves, A. K. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1139-4_4 · Cited by 10
“The low efficiency of the N1::CreLO allele created sporadic clones of cells with Notch1 loss of heterozygosity (LOH) in these mice, which subsequently experienced widespread vascular tumors and lethality secondary to massive hemorrhage (56).”
BackgroundIdentifying Direct Notch Transcriptional Targets Using the GSI-Washout Assay
Bailis, W., Yashiro–Ohtani, Y., & Pear, W. S. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1139-4_19 · Cited by 9
Metadata
- Authors
- Liu, Z., Turkoz, A., Jackson, E. N., Corbo, J. C., Engelbach, J. A., Garbow, J. R., Piwnica-Worms, D. R., & Kopan, R.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Kopan, Raphael
- Venue
- Journal of Clinical Investigation
- Published
- 2011-02-01
- Volume
- 121
- Issue
- 2
- Pages
- 800-808
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3026721
- OpenAlex
- W2145967409
- Cited by
- 119
- References
- 45
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 12 · 2014: 15 · 2013: 18 · 2012: 10
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Alvin J. Siteman Cancer Center
- National Institutes of Health
- National Eye Institute (R01EY018826)
- National Cancer Institute (P30 CA 91842, U24CA083060, U24 CA83060, P50CA094056, P30CA091842)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK066408)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- Notch1, loss of heterozygosity, tumor suppressor function, vascular tumors, hemorrhage, Notch signaling, conditional alleles, drug safety, mouse model
- MeSH terms
- Animals, Hemorrhage, Humans, Magnetic Resonance Imaging, Recombinant Fusion Proteins, Signal Transduction, Survival Rate, Disease Progression, Vascular Neoplasms, Loss of Heterozygosity, Mice, Receptor, Notch1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.